SeaStar Medical Holding Corporation is a biotechnology company headquartered in Denver, Colorado, specializing in the development and commercialization of medical devices for critically ill patients. The company operates through its patented Selective Cytopheretic Device (SCD) technology platform, which is designed to address life-threatening conditions in acute care settings. Its lead commercial product is QUELIMMUNE (SCD-PED) therapy, which received FDA approval under a Humanitarian Device Exemption for treating acute kidney injury due to sepsis in critically ill pediatric patients undergoing renal replacement therapy. The company focuses on bringing innovative therapeutic solutions to market within the surgical and medical instruments sector, serving healthcare providers and patients in need of advanced treatment options for severe acute conditions.